Tag: SDRL

Blue Horseshoe Stocks: EXAD Recap & More

Experience Art & Design, Inc. EXAD – Update

We began tracking EXAD off of its bottom at the beginning of last week, at which time we observed a low of .0009 in the stock. We were pleased with its steady albeit limited progress throughout the course of the week as it registered higher lows each day.

Then on Friday, the uptrend really kicked into high gear as we observed an impressive daily trading range from the open at its low of .001 to the close at it high of .0024. That worked out to a 140% intraday swing, and an overall increase of 167% over our observed low on Monday.

With the stock exhibiting momentum-play characteristics, we’ll certainly want to leave a slot open for it on our radar as we kick off a new trading week. In order to hold our interest, EXAD will need to maintain support at or above .0015 on any consolidations.

Shire plc SHPG – Options Idea

We’re intrigued with the present situation on SHPG, a stock whose options chain provided us with multi-bag opportunities from an idea we submitted early this year. Last week, the company made headlines as one of their drugs received FDA approval for an expanded label (Link to PR below), and this morning, we’re seeing a notable gap-up occurring in premarket trading this morning.

We’re going to look into using the current situation to our advantage by monitoring a series of options calls. Our target range is going to be the SHPG Weekly $175-180 Calls. We’ll have these on watch throughout the course of the week.

Extended Watchlist:
ESDI, SOUP, GST, PUK, SDRL, TCK

Blue Horseshoe Stocks: Options Review, Fresh Ideas & More

Wynn Resorts Ltd. WYNN – Options Review

It was the wide range of options contracts we highlighted in the WYNN chain that stole the show among our interests from yesterday morning’s premarket report.  We signaled the WYNN Weekly $93-96.50 Calls for observation, and not surprisingly, saw appreciable intraday gains from every single one of them.

Just take a look at the excellent single-session profits that were on the table for traders who fell in step with our idea. There was literally no way to go wrong with these selections, but at the top end of the range, the $96.50’s were obviously the star of the show with a nearly incomprehensible intraday move of more than 2700%!

$93 Calls – Trading Range: 2.98-7.68 – Max Gain: 158%
$93.50 Calls – Trading Range: 3.61-7.15 – Max Gain: 98%
$94 Calls– Trading Range: 2.53-6.20 – Max Gain: 145%
$94.50 Calls – Trading Range: 3.71-6.08 – Max Gain: 64%
$95 Calls – Trading Range: 2.40-5.62 – Max Gain: 134%
$95.50 Calls– Trading Range: 2.43-5.00 – Max Gain: 106%
$96 Calls – Trading Range: 1.47-5.00 – Max Gain: 240%
$96.50 Calls– Trading Range: .15-4.30 – Max Gain: 2766%

The stock is gapping up again this morning, so we expect the figures on these gains to be pushed even higher upon commencement of trading at the opening bell. We’ll also look for opportunities at a higher strike range with the $100-103 Calls as well.

Fresh Options Ideas

We’ve formulated a number of other options trading ideas to close out the week, but please heed our standard warning regarding Friday trading of weekly contracts- Only expert traders should attempt such a high-difficulty and risky venture. Both of the following are options chains from which we’ve pulled down mammoth gains on countless occasions in the past: 

SPDR S&P 500 ETF (SPY) – For the SPY, which of course is a general market analog, we’re going to be monitoring Weekly $205-207 Calls with both the general markets and oil gapping up this morning.

Petroleo Brasiliero S.A. (Petrobras) PBR – For PBR we’re zeroing in on the Weekly $5-6 Calls. PBR has made notable intraday upswings on more than one occasion this week, and a continuation of that pattern could lead to some nice gain figures for these contracts.

Extended Watchlist:
FRFS, MAXD, AVXL, AXAS, LEI, ORIG, SDRL, UWTI, WTI, BGMD(Bottom-bouncer)

Blue Horseshoe Stocks: Fresh Options Ideas & More

Pazoo Inc. PZOO

PZOO has been progressing well in the past several sessions since we last touched base with the stock a couple of weeks ago. We had just received word from the company that its wholly-owned CannabisKing Distribution subsidiary had struck two significant deals (Links to PR’s below), and witnessed a two-session swing of 74% as a result.

After regrouping and bouncing off of a low of .0046 (07/13), PZOO has made continuously higher lows for the rest of this month, and pushed its PPS back to the current range (.006-.007). We’ve provided the following snapshot illustrating the current bullish characteristics of the chart.

We’ll be on the lookout for further updates regarding the many irons PZOO currently has in the fire, and you can be sure that we’ll pass them along as the stories develop.

Fresh Options Ideas

As we approach midweek with earnings drops in full swing, we’re going to formulate a few corresponding options ideas we feel have the potential to perform well:

Ford Motor Co. (F) – Ford set record North American profits and beat Wall St. expectations handily this morning. The stock is gapping up moderately, so we’re going to taking a look at F Weekly $14.50 and $15 Calls, which should produce some nice action.

Pfizer, Inc. PFE –  Pfizer also had an earnings beat on their Q2 release today, and our related options ideas will be to monitor PFE Weekly $34.50 and $35 Calls.

Baidu, Inc. BIDU – After an extreme analyst downgrade, BIDU is taking an absolute beating, and is leading us to include a rare idea on the bearish side of things; we’ll be tracking BIDU Weekly Puts in the $180-175 Range.

Cytori Therapeutics, Inc. CYTX

We also want to raise a flag on a familiar stock cropping up in the news feed this morning. Early this year we saw CYTX make a huge move, and after spending the last several months in a general downtrend, some FDA-related news out this morning could be just the thing to catalyze a reversal. We’ll be watching intently for that possibility; check out the news below.

Cytori Therapeutics, Inc. (CYTX) today announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness (androgenic alopecia). >> FULL PR

Extended Watchlist:
PGNX, SDRL, NYMX, AKS, RJET